Yuxuan Hao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuxuan Hao has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Guoyuan Cui
Department of Oncology Shengjing Hospital of China Medical University Shenyang China
1 shared publication- Li Yu
Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publication Xiaoye Zhang
Department of Oncology Shengjing Hospital of China Medical University Shenyang China
1 shared publicationXiaoying Qi
Department of Oncology Shengjing Hospital of China Medical University Shenyang China
1 shared publicationZhongxiu Jiang
Department of Oncology Shengjing Hospital of China Medical University Shenyang China
1 shared publication
Latest Publications
- Open Access
- 21 May 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (10) , e7296
Clinicopathological features, prognostic factor analysis, and survival nomogram of patients with double primary cancers involving lung cancer
Background: Although the incidence of double primary cancers (DPCs) involving lung cancer is rising, they have not been studied sufficiently. This study retrospectively analyzed the clinicopathological and prognostic characteristics of DPC patients with lung cancer and developed a survival nomogram to predict the individual OS rates.Methods: We included 103 DPC patients with lung cancer from Shengjing Hospital between 2016 and 2021. Based on the 6‐month cancer occurrence interval, the cases were categorized as synchronous DPCs (sDPCs) or metachronous DPCs (mDPCs). Furthermore, the mDPCs were subdivided based on whether the lung cancer occurred first (LCF cohort) or the other cancer occurred first (OCF cohort).Results: Among the patients, 35 (33.98%) and 68 (66.02%) had sDPCs and mDPCs, respectively. In the mDPCs cohort, 18 (26.47%) belonged to the LCF cohort and 50 (73.53%) to the OCF cohort. The most frequent primary cancer sites were the breast (27.18%), colorectum (22.33%), and urinary system (18.45%). Independent risk factors for progression‐free survival were Stage IV lung cancer (p = 0.008) and failure to undergo radical lung cancer surgery (p = 0.028). The risk factors for OS included squamous carcinoma (p = 0.048), Stage IV lung cancer (p = 0.001), single cancer resection plus drug therapy (p < 0.001), drug therapy alone (p = 0.002), failure to undergo radical lung cancer surgery (p = 0.014), and chemotherapy (p = 0.042). The median OS was 37 months, with 3‐ and 5‐year rates of 50.9% and 35.9%, respectively.Conclusion: DPCs involving lung cancer account for 1.11% of cases. The breast, colorectum, and urinary system were the most common extra‐pulmonary sites, and mDPCs were more frequent than sDPCs. Radical lung cancer surgery significantly affects prognosis, and drug therapy alone may be preferable when only one tumor is operable. The developed nomogram can accurately predict individual 3‐year and 5‐year OS rates.
- 21 May 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (10) , e7296
Open AccessClinicopathological features, prognostic factor analysis, and survival nomogram of patients with double primary cancers involving lung cancer
Background: Although the incidence of double primary cancers (DPCs) involving lung cancer is rising, they have not been studied sufficiently. This study retrospectively analyzed the clinicopathological and prognostic characteristics of DPC patients with lung cancer and developed a survival nomogram to predict the individual OS rates.Methods: We included 103 DPC patients with lung cancer from Shengjing Hospital between 2016 and 2021. Based on the 6‐month cancer occurrence interval, the cases were categorized as synchronous DPCs (sDPCs) or metachronous DPCs (mDPCs). Furthermore, the mDPCs were subdivided based on whether the lung cancer occurred first (LCF cohort) or the other cancer occurred first (OCF cohort).Results: Among the patients, 35 (33.98%) and 68 (66.02%) had sDPCs and mDPCs, respectively. In the mDPCs cohort, 18 (26.47%) belonged to the LCF cohort and 50 (73.53%) to the OCF cohort. The most frequent primary cancer sites were the breast (27.18%), colorectum (22.33%), and urinary system (18.45%). Independent risk factors for progression‐free survival were Stage IV lung cancer (p = 0.008) and failure to undergo radical lung cancer surgery (p = 0.028). The risk factors for OS included squamous carcinoma (p = 0.048), Stage IV lung cancer (p = 0.001), single cancer resection plus drug therapy (p < 0.001), drug therapy alone (p = 0.002), failure to undergo radical lung cancer surgery (p = 0.014), and chemotherapy (p = 0.042). The median OS was 37 months, with 3‐ and 5‐year rates of 50.9% and 35.9%, respectively.Conclusion: DPCs involving lung cancer account for 1.11% of cases. The breast, colorectum, and urinary system were the most common extra‐pulmonary sites, and mDPCs were more frequent than sDPCs. Radical lung cancer surgery significantly affects prognosis, and drug therapy alone may be preferable when only one tumor is operable. The developed nomogram can accurately predict individual 3‐year and 5‐year OS rates.